DPH2 gene deletion mutant and uses thereof
AssigneesManuel Caruso, Vincent Roy
InventorsManuel Caruso, Vincent Roy
Life of this patent
Estimating the term…
Abstract
Diphtheria and Pseudomonas infections are very common worldwide. The toxins involved in the pathogenesis of those diseases act by inactivating the elongation factor-2 (EF-2), therefore blocking protein synthesis and leading to cell death. Diphthamide formation on EF-2 is a prerequisite step in the inactivation of EF-2, and Dph proteins have been identified as modulating this process. The present application concerns Dph2 deletion mutant genes and proteins and their uses in vitro and in vivo.
Claims1
A method for inhibiting in vitro the formation of diphthamide in a human cell having wild-type dph-2 gene expressing wild-type Dph2(C-) protein, the method comprising:
- introducing a dominant negative Dph2(C-) protein in said cell, wherein said dominant negative Dph2(C-) protein is selected from the group consisting of:
- SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 and SEQ ID NO:10, whereby said dominant negative protein Dph2(C-) inhibits said wild-type Dph2(C-) protein activity originally present in said human cell.
Dependencies are inferred from the claim text.